We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+69.49%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$617M
AUM Growth
–
Cap. Flow
+$516M
Cap. Flow %
83.64%
Top 10 Hldgs %
46.54%
Holding
114
New
114
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$16.4M
2
CHMA
Chiasma, Inc. Common Stock
CHMA
+$5.74M
3
IMVT icon
Immunovant
IMVT
+$5.65M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.43M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.34M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 16.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
101
Dianthus Therapeutics
DNTH
$5.55B
$131K 0.02%
+542
New +$101K
ARVN icon
102
CALL
Arvinas
ARVN
$529M
$127K 0.02%
+3,100
New +$90.8K
ARVN icon
103
PUT
Arvinas
ARVN
$529M
$127K 0.02%
+3,100
New +$90.8K
MITO
104
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$123K 0.02%
+37,597
New +$288K
MGNX icon
105
MacroGenics
MGNX
$245M
$109K 0.02%
+10,030
New +$99.3K
XFOR icon
106
X4 Pharmaceuticals
XFOR
$371M
$107K 0.02%
+333
New +$119K
CSCI
107
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$107K 0.02%
+1,174
New +$109K
NVAX icon
108
Novavax
NVAX
$1.21B
$100K 0.02%
+25,049
New +$109K
PVLA
109
CALL
Palvella Therapeutics
PVLA
$2.05B
$80K 0.01%
+275
New +$76.2K
TVRD
110
PUT
Tvardi Therapeutics
TVRD
$22.9M
$68K 0.01%
+117
New +$82.1K
VIRX
111
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$38K 0.01%
+3,184
New +$53.3K
BHVN
112
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$35K 0.01%
+642
New +$31.8K
ALPN
113
DELISTED
Alpine Immune Sciences Inc
ALPN
$18K ﹤0.01%
+4,739
New +$14.8K
APLS
114
DELISTED
Apellis Pharmaceuticals
APLS
$2K ﹤0.01%
+53
New +$1.47K
1 2 3 4
5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Ikarian Capital, which disclosed 114 positions worth $617M. Its ten largest holdings account for 47% of the portfolio.

Its largest position is Sage Therapeutics: 133,000 shares worth $9.6M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets.

  • Ikarian Capital's largest Q4 2019 buy was Sage Therapeutics: 133,000 shares worth $9.6M.
  • Ikarian Capital's ten largest holdings make up 47% of its $617M portfolio in Q4 2019.
  • Ikarian Capital disclosed 114 positions in Q4 2019, its first 13F filing on record.

Based on Ikarian Capital's 13F filing for Q4 2019, filed 31 Jan 2020.